» Articles » PMID: 35132181

Active Demethylation Upregulates CD147 Expression Promoting Non-small Cell Lung Cancer Invasion and Metastasis

Overview
Journal Oncogene
Date 2022 Feb 8
PMID 35132181
Authors
Affiliations
Soon will be listed here.
Abstract

Non-small cell lung cancer (NSCLC) is a fatal disease, and its metastatic process is poorly understood. Although aberrant methylation is involved in tumor progression, the mechanisms underlying dynamic DNA methylation remain to be elucidated. It is significant to study the molecular mechanism of NSCLC metastasis and identify new biomarkers for NSCLC early diagnosis. Here, we performed MeDIP-seq and hMeDIP-seq analyses to detect the genes regulated by dynamic DNA methylation. Comparison of the 5mC and 5hmC sites revealed that the CD147 gene underwent active demethylation in NSCLC tissues compared with normal tissues, and this demethylation upregulated CD147 expression. Significantly high levels of CD147 expression and low levels of promoter methylation were observed in NSCLC tissues. Then, we identified the CD147 promoter as a target of KLF6, MeCP2, and DNMT3A. Treatment of cells with TGF-β triggered active demethylation involving loss of KLF6/MeCP2/DNMT3A and recruitment of Sp1, Tet1, TDG, and SMAD2/3 transcription complexes. A dCas9-SunTag-DNMAT3A-sgCD147-targeted methylation system was constructed to reverse CD147 expression. The targeted methylation system downregulated CD147 expression and inhibited NSCLC proliferation and metastasis in vitro and in vivo. Accordingly, we used cfDNA to detect the levels of CD147 methylation in NSCLC tissues and found that the CD147 methylation levels exhibited an inverse relationship with tumor size, lymphatic metastasis, and TNM stage. In conclusion, this study clarified the mechanism of active demethylation of CD147 and suggested that the targeted methylation of CD147 could inhibit NSCLC invasion and metastasis, providing a highly promising therapeutic target for NSCLC.

Citing Articles

The role of DNA methylation and DNA methyltransferases (DNMTs) as potential biomarker and therapeutic target in non-small cell lung cancer (NSCLC).

Mohd Kamal K, Ghazali A, Ab Mutalib N, Abu N, Chua E, Masre S Heliyon. 2024; 10(19):e38663.

PMID: 39403460 PMC: 11472108. DOI: 10.1016/j.heliyon.2024.e38663.


Epigenetic Modifiers in Cancer Metastasis.

Hu D, Zhao T, Xu C, Pan X, Zhou Z, Wang S Biomolecules. 2024; 14(8).

PMID: 39199304 PMC: 11352731. DOI: 10.3390/biom14080916.


DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer.

Tasiheng Y, Lin X, Zou X, Chen Y, Yan Y, Ma M Cancer Immunol Immunother. 2024; 73(10):208.

PMID: 39110249 PMC: 11306721. DOI: 10.1007/s00262-024-03786-3.


N-methyladenosine-modified SRPK1 promotes aerobic glycolysis of lung adenocarcinoma via PKM splicing.

Wang A, Zeng Y, Zhang W, Zhao J, Gao L, Li J Cell Mol Biol Lett. 2024; 29(1):106.

PMID: 39095708 PMC: 11295518. DOI: 10.1186/s11658-024-00622-5.


TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis.

Liu P, Xie L, Wu Q, Huang L, Liu X, Li W Int J Biol Sci. 2024; 20(6):2297-2309.

PMID: 38617545 PMC: 11008262. DOI: 10.7150/ijbs.93667.


References
1.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

2.
Zhang J, Mao W, Chen Z, Gu H, Lian C . Clinical Significance of Has_circ_0060937 in Bone Metastasis of NSCLC. Int J Gen Med. 2020; 13:1115-1121. PMC: 7670089. DOI: 10.2147/IJGM.S279023. View

3.
Wang H, Zhang Y, Zhu H, Yu J . Risk factors for bone metastasis in completely resected non-small-cell lung cancer. Future Oncol. 2016; 13(8):695-704. DOI: 10.2217/fon-2016-0237. View

4.
Kinnaird A, Zhao S, Wellen K, Michelakis E . Metabolic control of epigenetics in cancer. Nat Rev Cancer. 2016; 16(11):694-707. DOI: 10.1038/nrc.2016.82. View

5.
Wang Q, Dai L, Wang Y, Deng J, Lin Y, Wang Q . Targeted demethylation of the SARI promotor impairs colon tumour growth. Cancer Lett. 2019; 448:132-143. DOI: 10.1016/j.canlet.2019.01.040. View